Research Area
This laboratory studies the human immune response to infection for a wide variety of major human pathogens, including many emerging infections. The research group uses a very broad array of techniques including molecular and cellular biology, state-of-the-art imaging and flow cytometry, bioinformatics, and bioengineering approaches to attack scientific problems at the forefront of immunity research. Many vaccine candidates and human monoclonal antibodies developed during t team’s research have been tested in Phase I-III clinical trials in humans, including tixagevimab + cilgavimab (Evusheld) that obtained EUA or full approval from the US FDA and European EMA for preventing COVID-19 with over 3 million treatments given to patients in the US, Europe, Middle East, Africa and Australia. They also started the company IDBiologics and the nonprofit Global Pandemic Prevention and Biodefense Center, home of the AHEAD100 initiative, to discover antibody drugs for 100 emerging infections.
Team Description
This diverse team of antibody scientists is comprised of wet lab scientists (virology, immunology, and vaccine sciences), computational biologists, project managers and clinical research experts. The team has members who are graduate students, postdocs, staff scientists, faculty and staff. Team members bring a high degree of diversity to the work, with individuals from over a dozen countries, strong women scientists, and members from groups historically underrepresented in science. The team's work has been highly recognized for excellence, with awards such as TIME - The Best Innovations of 2022; R&D100 award and a R&D100 Gold Medal (“Oscars of Innovation”), San Diego; Best Academic Research Team, 11th Annual Vaccine Industry Excellence Awards, World Vaccine Congress and others.
Team Members
Team Show
Publications
Lat 2 years only:
Dagotto G, Mercado N, Martinez D, Hou Y, Nkolola J, Carnahan R, Crowe JE Jr, Baric R, Barouch D. Comparison of subgenomic and total RNA in SARS-CoV-2 challenged rhesus macaques. Journal of Virology
2021; 95(8):e02370-20. PMC ID 8103707.
Winkler ES, Gilchuk P, Yu J, Bailey AL, Chen RE, Zost SJ, Jang H, Huang Y, Allen JD, Case JB, Sutton RE, Carnahan RH, Darling TL, Boon ACM, Mack M, Head RD, Ross TM, Crowe JE Jr, Diamond MS. Human neutralizing antibodies against SARS-1 CoV-2 require intact Fc effector functions and monocytes for optimal therapeutic protection. Cell 2021; 184:1804-1820.e16. PMC ID 7879018.
Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, Liu J, Errico JM, Xie X, Suryadevara N, Gilchuk P, Zost SJ, Tahan S, Droit L, Turner JS, Kim W, Schmitz AJ, Thapa M, Wang D, Boon ACM, Presti RM, O'Halloran JA, Kim AHJ, Deepak P, Pinto D, Fremont DH, Crowe JE Jr, Corti D, Virgin HW, Ellebedy AH, Shi PY, Diamond MS. Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine 2021; 27:717-726. PMC ID 8058618.
Chapman NS, Zhao H, Kose N, Westover JB, Kalveram B, Bombardi R, Rodriguez J, Sutton R, Genualdi J, LaBeaud AD, Mutuku FM, Pittman, Freiberg AN, Gowen BG, Fremont DH, Crowe JE Jr. Potent neutralization of Rift Valley fever virus by human monoclonal antibodies through fusion inhibition. Proceedings of the National Academy of Sciences USA 2021; 118(14):e2025642118. PMC ID 8040655.
Suryadevara N, Shrihari S, Gilchuk P, VanBlargan L, Binshtein E, Zost S, Nargi R, Sutton R, Winkler ES, Chen EC, Fouch ME, Davidson E, Doranz B, Carnahan RM Jr, Thackray L, Diamond MS, Crowe JE Jr. Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein. Cell 2021; 184:2316-2331.e15. PMC ID 7962591.
Murin CD, Gilchuk P, Ilinykh PA, Huang K, Kuzmina N, Shen X, Bruhn JF, Bryan AL, Davidson E, Doranz BJ, Williamson LE, Copps J, Alkutkar T, Flyak AI, Bukreyev A, Crowe JE Jr, Ward AB. Convergence of a common solution to broad ebolavirus neutralization by glycan cap directed human antibodies. Cell Reports 2021; 35(2):108984. PMC ID 8133395.
Schoeder CT, Schmitz S, Adolf-Bryfogle J, Sevy, A, Finn J, Sauer MF, Bozhanova NG, Mueller BK, Sangha A, Bonet J, Sheehan J, Juenze G, Marlow B, Smith ST, Woods H, Martina CE, del Alamo D, Kodali P, Gulsevin A, Schief WR, Correia BE, Crowe Jr JE, Meiler J, Moretti R. Modeling immunity with Rosetta: methods for antibody and antigen design. Biochemistry 2021; 60:825-846. PMC ID 7992133.
Engdahl TB, Kuzmin NA, Ronk AJ, Mire CE, Hyde MA, Kose N, Josleyn MD, Sutton RE, Mehta A, Wolters RM, Lloyd NM, Valdivieso FR, Ksiazek TG, Hooper JW, Bukreyev A, Crowe JE Jr. Broad and potently neutralizing monoclonal antibodies isolated from human survivors of New World hantavirus infection. Cell Reports 2021; 36:109453. PMC ID 8357190.
VanBlargan L, Adams L, Liu Z, Chen RE, Gilchuk P, Raju S, Smith B, Zhao H, Case JB, Winkler ES, Whitener B, Droit L, Aziati I, Shi PY, Creanga A, Pegu A, Handley S, Wang D, Boon A, Crowe JE Jr, Whelan SPJ, Fremont D, Diamond M. A potently neutralizing anti-SARS-CoV-2 antibody inhibits variants of concern by binding a highly conserved epitope. Immunity 2021; 54:2399-2416.e6. PMC ID 8373659.
Shiakolas A, Kramer KJ, Wrapp D, Richardson SI, Schäfer A, Wall S, Wang N, Janowska K, Pilewski K, Venkat R, Parks R, Manamela NP, Raju N, Fechter EF, Holt CM, Suryadevara N, Chen RE, Martinez DR, Nargi RS, Sutton RE, Ledgerwood JE, Graham BS, Diamond MS, Haynes BF, Acharya P, Carnahan RH, Crowe JE Jr, Baric RS, Morris L, McLellan JS, Georgiev IS. Cross-reactive coronavirus antibodies with diverse epitope specificities and extra-neutralization functions. Cell Reports Medicine. 2021; 2:100313. PMC ID 8139315.
Zost SJ, Dong J, Gilchuk IM, Gilchuk P, Thornburg NJ, Bangaru S, Kose N, Finn JA, Bombardi R, Soto C, Nargi RS, Irving RP, Suryadevara N, Westover JB, Carnahan RH Jr, Turner HL, Li S, Ward AB, Crowe JE Jr. Canonical features of human antibodies recognizing the influenza hemagglutinin trimer interface. Journal of Clinical Investigation 2021; 131(15):e146791. PMC ID 8321569.
Kodali P, Schoeder CT, Schmitz S, Crowe JE Jr, Jens Meiler J. RosettaCM for antibodies with very long HCDR3s and low template availability. Proteins - Structure, Function, Bioinformatics 2021; 89:1458-1472. doi: 10.1002/prot.26166. PMC ID 8492515.
Alvarado G, Salmen W, Hu L, Sankaran B, Estes MK, Prasad BVV, Crowe JE Jr. Broadly cross-reactive human antibodies that inhibit genogroup I and II noroviruses. Nature Communications 2021; 12(1):4320. PMC ID 8280134. Author correction: Nature Communications 2021;12(1):6090. PMC ID 8516901.
Chen RE, Winkler ES, Case JB, Aziati ID, Bricker TL, Joshi A, Darling TL, Ying B, Errico JM, Shrihari S, VanBlargan LA, Xie X, Gilchuk P, Zost SJ, Droit L, Liu Z, Stumpf S, Wang D, Handley SA, Stine WE Jr, Shi P-Y, Davis-Gardner ME, Suthar MS, Garcia Knight MG, Andino R, Chiu CY, Ellebedy AH, Fremont DH, Whelan SPJ, Crowe JE Jr, Purcell L, Corti D, Boon ACM, Diamond MS. In vivo monoclonal antibody efficacy against SARS-CoV- variant strains. Nature 2021; 596:103-108. PMC ID 8349859.
Meyer M, Gunn B, Malherbe D, Gangavarapu K, Yoshida A, Pietzsch C, Kuzmina N, Saphire EO, Collins P, Crowe JE Jr, Zhu J, Suchard M, Brining D, Mire C, Cross R, Geisbert J, Samal S, Andersen K, Alter G, Geisbert T, Alexander Bukreyev A. The Ebola vaccine induced protection in non-human primates correlates with antibody Fc-mediated effects. Science Translational Medicine. 13(602):eabg6128. PMC ID 8675601.
Puray-Chavez M, LaPak KM, Schrank TP, Elliott JL, Bhatt DP, Agajanian MJ, Jasuja R, Lawson DQ, Davis K, Rothlauf PW, Liu Z, Jo H, Lee N, Tenneti K, Eschbach JE, Mugisha CS, Cousins EM, Cloer EW, Vuong HR, VanBlargan LA, Bailey AL, Gilchuk P, Crowe JE Jr, Diamond MS, Hayes DN, Whelan SPJ, Horani A, Brody SL, Goldfarb D, Major MB, Kutluay SB. Systematic analysis of SARS-CoV-2 infection of an ACE-negative human airway cell. Cell Reports 2021; 36:109364. PMC ID 8220945.
Drury SL, Miller AR, Laut CL, Walter AB, Bennett MR, Su M, Bai M, Jing B, Joseph SB, Edward J. Metzger EJ, Bane CE, Black CC, Macdonald MT, Dutter BF, Romaine IM, Waterson AG, Sulikowski GA, Jansen ED, Crowe JE Jr, Sciotti RJ, Skaar EP. Simultaneous exposure to intracellular and extracellular photosensitizers for the treatment of Staphylococcus aureus infections. Antimicrobial Agents and Chemotherapy 2021; 65(12):e0091921. PMC ID 8597735.
Kim AS, Kafai NM, Winkler ES, Earnest JT, Jethva P, Shah AP, Vang L, Davidson E, Williamson L, Crowe JE Jr, Doranz BJ, Lai JM, Gross ML, Klimstra WB, Fremont DH, Diamond MS. Pan-protective human monoclonal antibodies against alphaviruses target a conserved epitope in the E1 structural glycoprotein. Cell 2021; 184:4414-4429.e19. PMC ID 8382027.
Yadav SS, Gach JS, Wong MP, Diep KH, Matsuno SY, Bombardi RG, Nargi RS, Caldwell T, Becerra JC, Crowe JE Jr, Forthal D. The Fc neonatal receptor modulates antibody-dependent enhancement of dengue virus. In press, Journal of Immunology. PMC submission in process.
Gilchuk P, Guthals A, Bonissone S, Ilinykh PA, Huang K, Bombardi R, Bryan A, Davidson E, Chen E, Doranz BJ, Bukreyev A, Zeitlin L, Castellana N, Crowe JE Jr. Proteo-genomic analysis identifies two major sites of vulnerability on ebolavirus glycoprotein for neutralizing antibodies in convalescent human plasma. Frontiers in Immunology 2021; 12:706757. PMC ID 8322977.
Doyle MP, Kose N, Borisevich V, Binshtein E, Amaya M, Nagel M, Annand EJ, Armstrong E, Bombardi R, Dong J, L. Schey KL, C. Broder CC, Zeitlin L, Kuang EA, Bornholdt ZA, West BR, Geisbert TW, Cross RW, Crowe JE Jr. Functional cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein. Cell Reports 2021; 36:109628. PMC ID 8527959.
Williamson LW, Reeder KM, Bailey K, Roy V, Fouch ME, Kose N, Trivette A, Nargi RS, Winkler ES, Kim AS, Gainza C, Rodriguez J, Armstrong E, Sutton RE, Reidy J, Carnahan RH, Klimstra WB, Diamond MS, Davidson E, Doranz BJ, Alter G, Julander JG, Crowe JE Jr. Therapeutic alphavirus cross-reactive E1 human antibodies inhibit viral egress. Cell 2021; 184:4430-4446.e22. PMC ID 8418820.
Chen EC, Gilchuk P, Zost SJ, Suryadevara N, Winkler ES, Cabel CR, Binshtein E. Sutton RE, Rodriguez J, Day S, Myers L, Trivette A, Williams JK, Davidson E, Li S, Doranz BJ, Campos SK, Carnahan RH, Thorne CA, Diamond MS, Crowe JE Jr. Convergent antibody responses to the SARS-CoV-2 spike protein in convalescent and vaccinated individuals. Cell Reports. 2021; 36(8):109604. PMC ID 8352653.
Gilchuk IM, Bangaru S, Kose N, Bombardi RG, Trivette A, Li S, Turner HL, Carnahan RH, Ward AB, Crowe JE Jr. Human antibody recognition of the antigenic landscape on H7N9 influenza virus hemagglutinin following natural infection. Journal of Clinical Investigation Insight 2021; 6(19):e152403. PMC ID 8525637.
Dong J, Zost SJ, Greaney AJ, Starr TN, Dingens AS, Chen EC, Chen RE, Case JB, Sutton RE, Gilchuk P, Rodriguez J, Armstrong E, Gainza C, Nargi RS, Binshtein E, Xie X, Zhang X, Shi P-Y, Logue J, Weston S, McGrath ME, Frieman MB, Brady T, Tuffy K, Bright H, Loo Y-M, McTamney P, Esser M, Carnahan RH, Diamond MS, Bloom JD, Crowe JE Jr. Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail. Nature Microbiology 2021; 6(10):1233-1244. PMC ID 8543371.
August A, Attarwala H, Himansu S, Kalidindi S, Lu S, Tomassini JE, Hard M, Ptaszek L, Crowe JE Jr, Diamond MS, Zaks T. A phase 1 trial demonstrating mRNA can encode and produce potentially therapeutic levels of a monoclonal antibody with neutralizing activity against chikungunya virus. Nature Medicine 2021; 27:2224–2233. PMC ID 8674127.
Wessel AW, Doyle MP, Engdahl TB, Rodriguez J, Crowe JE Jr*, Diamond MS*. Human monoclonal antibodies against NS1 protein protect against lethal West Nile virus infection. mBio 2021; 12(5):e0244021. PMC ID 8510529.
*corresponding.
Kilgore JM, Davidson E, Kadash-Edmondson K, Hernandez M, Rosenberg E, Chambers R, Castelli M, Clementi N, Mancini N, Bailey JR, Crowe JE Jr, Law M, Doranz BJ. Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Reports 2021; 39(8):110859. PMC ID 9281441.
Gilchuk P, Murin CD, Cross RW, Ilinykh PA, Huang K, Kuzmina N, Borisevich V, Agans KN, Geisbert JB, Carnahan RH, Nargi RS, Sutton RE, Suryadevara N, Zost SJ, Bombardi RG, Bukreyev A, Geisbert TW, Ward AB, Crowe JE Jr. Protective pan-ebolavirus combination therapy by two multifunctional human antibodies. Cell 2021; 184(22):5593-5607.e18. PMC ID 8716180.
Kramer KJ, Johnson NV, Shiakolas AR, Suryadevara N, Periasamy S, Raju N, Wrapp D, Zost SJ, Holt C, Hsieh C-L, Kuzmina N, Nargi R, Sutton RE, Paulo A, Davidson E, Crowe JE Jr, Bukreyev A, Carnahan RH, McLellan JS, Georgiev IS. Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. Cell Reports 2021; 37(1):109784. PMC ID 8443366.
Cobb RR, Nkolola J, Gilchuk P, Chandrashekar A, House RV, Earnhart CG, Dorsey NM, Hopkins SA, Snow DM, Chen RE, VanBlargan LA, Hechenblaikner M, Hoppe B, Collins L, Tomic MT, Nonet GH, Hackett K, Slaughter JC, Diamond MS, Carnahan RH, Barouch DH, Crowe JE Jr. A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in rhesus macaques. Med (NY) 2022; 3(3):188-203.e4. PMC ID 8810411.
Shiakolas AR, Johnson N, Kramer KJ, Suryadevara N, Wrapp D, Periasamy S, Pilewski KA, Raju N, Nargi R, Sutton RE, Walker L, Crowe JE Jr, Bukreyev A, Carnahan RH, McLellan JS, Georgiev IS. Efficient discovery of potently neutralizing SARS-CoV-2 antibodies using LIBRA-seq with ligand blocking. Nature Biotechnology 2022. Mar 3. doi: 10.1038/s41587-022-01232-2. Online ahead of print. PMID: 35241839.
Yuan TZ, Garg P, Willis JR, Kwan E, Hernandez AGL, Tuscano E, Sever EN, Soto C, Hooper JW, Doranz BJ, Fouch ME, Davidson E, Kailasan S, Aman MJ, Li H, Saphire EO, Crowe JE Jr, Liu Q, Axelrod F, Sato AK. Rapid discovery of diverse neutralizing SARS-CoV-2 antibodies from large-scale phage libraries. MAbs 2022 14(1) 2002236. PMC ID 8726723.
Loo Y-M, McTamney P, Arends R, Gasser RA Jr, Abrams M, Aksyuk A, Diallo S, Flores D, Kelly B, Ren K, Roque R, Rosenthal K, Streicher K, Tuffy KM, Bond NJ, Cornwall O, Bouquet J, Cheng L, Dunyak J, Huang Y, Rosenbaum, Andersen H, Carnahan R, Crowe JE Jr , Kuehne A, Herbert A, Dye J, Bright H, Kallewaard-LeLay N, Pangalos MN, Esser MT, On behalf of the AstraZeneca AZD7442 Study Group. The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in non-human primates and has an extended half-life in humans. Science Translational Medicine 2022; 14(635):eabl8124. PMC ID 8939769.
Gilchuk P, Thomsen I, Yoder S, Brady E, Chappell JD, Stevens LJ, Denison MR, Sutton RE, Suryadevara N, Chen RE, Zost SJ, Schmitz J, Pulley JM, Diamond MS, Rhodes J, Stewart TG, Bernard GR, Self WH, Rice TW, Wheeler AP, Crowe JE Jr, Carnahan RH. Standardized two-step testing of antibody-based interventions against SARS-CoV-2. iScience 2021. 25:103602. PMC ID 8653399.
Ogega CO, Skinner NE, Flyak AI, Clark KE, Board N, Bjorkman PJ, Crowe JE Jr, Cox AL, Ray SC, Bailey JR. B cell overexpression of FCRL5 and PD-1 is associated with low antibody titers in HCV infection. PLoS Pathogens 2022; 18(1):e1010179. PMC ID 8769295.
VanBlargan LA, Errico JM, Halfmann P, Zost SJKafai NM, Williamson LE, Binshtein E, Sukupolvi-Petty S, Gardner CL, Liu J, Mackin S, Kim AS, Kose N, Carnahan RH, Jung A, Droit L, Reed DS, Handley S, Klimstra WB, Crowe JE Jr, Kawaoka Y, Corti D, Fremont DH, Diamond MS. An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies. Nature Medicine 2022; 28(3):490-495. PMC ID 8767531.
Kafai NM, Williamson LE, Binshtein E, Sukupolvi-Petty S, Gardner CL, Ryckman ZJ, Liu J, Kim AS, Kose N, Carnahan RH, Jung A, Droit L, Handley SA, Klimstra WB, Crowe JE Jr, Diamond MS. Neutralizing monoclonal antibodies protect against Venezuelan equine encephalitis virus aerosol challenge. Journal of Experimental Medicine 2022; 219(4):e20212532. PMC ID 9195047.
Hu L, Salmen W, Chen R, Zhou Y, Neil F, Crowe JE Jr, Atmar RL, Estes MK, Prasad B.V.V. Atomic structure of the predominant GII.4 human norovirus capsid reveals novel stability and plasticity. Nature Communications 2022; 13(1):1241. PMC ID 8913647.
Bangaru S, Antanasijevic A, Kose N, Sewall LM, Jackson AM, Suryadevara N, Zhan X, Torres JL, Copps J, Torrents de la Peña A, Crowe JE Jr, Ward AB. Structural mapping of antibody landscapes to human betacoronavirus spike proteins. Science Advances 2022; 8(18):eabn2911. PMC ID 9067923.
Doyle MP, Genualdi JR, Bailey AL, Kose N, Nelson CA, Nargi R, Sutton RE, Bombardi RG, Julander JG, Fremont DH, Diamond MS, Crowe JE Jr. A human monoclonal antibody targeting the yellow fever virus envelope protein domain II potently neutralizes at a pre-attachment step and protects animals from authentic virus challenge. mBio 2022; 13(3):e0051222. PMC ID 9239089.
Suryadevara N, Gilchuk P, Zost SJ, Mittal N, Zhao LL, Crowe JE Jr, Carnahan RH. Real-time cell analysis: A high-throughput approach for testing SARS-CoV-2 antibody neutralization and escape. Star Protocols 2022; 3(2) 101387. PMC ID 9023333.
Vogt MR, Wright PF, Hickey WF, Boyd KL, Crowe JE Jr. Enterovirus D68 in anterior horn cells of a child with acute flaccid myelitis. New England Journal of Medicine 2022; 386(21):2059-2060. doi: 10.1056/NEJMc2118155. PMC ID 9321432.
Suryadevara N, Shiakolas A, VanBlargan L, Binshtein E, Chen R, Case JB, Kramer K, Armstrong E, Myers L, Trivette A, Gainza C, Nargi N, Selverian C, Davidson E, Doranz B, Diaz S, Handal L, Carnahan RH, Diamond MS, Georgiev I, Crowe JE Jr. An antibody targeting the N-terminal domain of SARS-CoV-2 disrupts the spike trimer. Journal of Clinical Investigation 2022; 132(11):e159062. PMC ID 9151704.
Fowler, BD, Kose N, Reidy JX, Handal LS, Skaar EP*, Crowe JE Jr*. Human monoclonal antibodies to Escherichia coli outer membrane protein A porin domain cause aggregation but do not alter in vivo bacterial burdens in a murine sepsis model. Infection and Immunity 2022; 90(6):e0017622. PMC ID 9202393. *co-corresponding.
Nkolola JP, Yu J, Wan H, Chang A, McMahan K, Anioke T, Jacob-Dolan C, Powers O, Tiayi Ye T, Chandrashekar A, Sellers D, Barrett J, Loo Y-M, Esser MT, Carnahan RH, Crowe JE Jr, Barouch DH.
A bivalent SARS-CoV-2 monoclonal antibody combination does not impact the immunogenicity of a vector-based COVID-19 vaccine in macaques. Science Translational Medicine 2022; 14(665):eabo6160. PMC ID 9348747.
Pfaff-Kilgore J, Davidson E, Kadash-Edmondson K, Hernandez M, Rosenberg E, Chambers R, Castelli M, Clementi N, Mansini N, Bailey JR, Crowe JE Jr, Law M, Doranz BJ. Sites of vulnerability in HCV E1E2 identified by comprehensive functional screening. Cell Reports 2022; 39:110859. PMC ID 9281441.
Schmitz S, Schmitz EA, Crowe JE Jr, Meiler J. The human antibody sequence space and structural design of the V, J, and CDRH3 domains with Rosetta. mAbs 2022; 14:1, PMC ID 9103704.
Frumento N, Figueroa A, Wang T, Zahid MN, Wang S, Massaccesi G, Stavrakis G, Crowe JE Jr, Flyak AI, Hongkai Ji H, Ray SC, Shaw GM, Cox AL, Bailey JR. Repeated exposure to heterologous but antigenically related hepatitis C viruses is associated with induction of potent and broadly neutralizing antibodies. Journal of Clinical Investigation 2022; 132(15):e160058. PMC ID 9337827.
Bozhanova NG, Flyak AI, Ruiz SE, Salas J, Rho S, Bombardi RG, Myers L, Soto C, Bailey JR, Crowe JE Jr, Bjorkman PJ, Meiler J. Computational identification of HCV neutralizing antibodies with a common HCDR3 disulfide bond motif in the antibody repertoires of infected individuals. Nature Communications 2022; 13(1):3178. PMC ID 9177688.
Case JB, Mackin S, Errico J, Madden EA, Guarino B, Oladunni F, Wang C, Rosentha K, Ren K, Jung A, Droit L, Handley SA, Halfmann PJ, Kawaoka Y, Crowe JE Jr, Fremont DH, Virgin HW, Loo Y-M, Purcell L, Davide Corti D, Diamond MS. Resilience of S309 and AZD442 monoclonal antibody treatments against infection by SARS-CoV-Omicron lineage strains. Nature Communications 2022; 13(1):3824. PMC ID 9250508.
Kramer KJ, Wilfong EM, Voss K, Barone SM, Shiakolas AR, Raju N, Roe CE, Suryadevara N, Walker L, Wall SC, Paulo A, Schaefer S, Dahunsi D, Westlake CS, Hsieh C-L, McLellan JS, Crowe JE Jr, Carnahan RH, Rathmell JC, Bonami RH, Georgiev IS, Irish JM. Single-cell profiling of the antigen-specific response to BNTb SARS-CoV- RNA vaccine. Nature Communications 2022; 13(1):3466. PMC ID 9201272.
Self WH, Wheeler AP, Stewart TG, Schrager H, Mallada J, Thomas CB, Cataldo VD, O’Neal HR, Shapiro NI, Higgins C, Ginde AA, Chauhan L, Johnson NJ, Henning DJ, Jaiswal SJ, Mammen MJ, Harris ES, Pannu SR, Laguio-Vila M, El Atrouni W, de Wit M, Hoda D, Cohn CS, McWilliams C, Shanholtz C, Jones AE, Raval JS, Mucha S, Ipe TS, Qiao X, Schrantz SJ, Shenoy A, Fremont RD, Brady EJ, Carnahan RH, Chappell JD, Crowe JE, Denison MR, Gilchuk P, Stevens LJ, Sutton RE, Thomsen I, Yoder SM, Bistran-Hall AJ, Casey JD, Lindsell CJ, Wang L, Pulley JM, Rhoads JP, Bernard GR, Rice TW, For the Passive Immunity Trial for Our Nation (PassITON) Investigators. Neutralizing COVID-19 convalescent plasma in adults hospitalized with COVID-19: A blinded randomized placebo-controlled trial. Chest 2022, Jun 30:S0012-3692(22)01201-6. doi: 10.1016/j.chest.2022.06.029. Online ahead of print. PMC ID 9247217.
Ford-Siltz LA, Tohma L, Alvarado G, Kendra JA, Pilewski KA, Crowe JE Jr, Parra GI. Cross-reactive neutralizing human monoclonal antibodies mapping to variable antigenic sites on the norovirus major capsid protein. Frontiers in Immunology 2022; 25 13: 1040836. PMC ID 9641292.
Vanover D, Rotolo L, Zurla C, Peck HE, Orr-Burks N, Murray J, Nathan Holladay N, Joo JY, Hobbs RA, Lifland AW, Olivier AK, Crowe JE Jr, Haynes BF, Lafontaine ER, Hogan RJ, Santangelo PJ. Nebulized mRNA-encoded antibodies protect hamsters from SARS-CoV-2 infection. Advanced Science 2022; 9(34):e2202771. doi: 10.1002/advs.202202771. PMC ID 9731714.
Chen EC, Gilchuk P, Zost SJ, Ilinykh PA, Binshtein E, Huang K, Myers L, Bonissone S, Day S, Kona CR, Trivette A, Reidy JX, Sutton RE, Gainza C, Monroig S, Davidson E, Saphire EO, Doranz BJ, Castellana N, Bukreyev A, Carnahan RH, Crowe JE Jr. Systematic analysis of human antibody response to ebolavirus glycoprotein reveals high prevalence of neutralizing public clonotypes. In press, Cell Reports 2023; 42(4):112370. doi: 10.1016/j.celrep.2023.112370. PMID: 37029928. PMC ID in process.
Raju N, Zhan X, Das S, Karwal L, Dean HJ, Crowe JE Jr, Carnahan RH, Georgiev IS. Neutralization fingerprinting technology for characterizing polyclonal antibody responses to dengue vaccines. Cell Reports 41, 111807. https://doi.org/10.1016/j.celrep.2022.111807. PMID: 36516766.
Fischer MFS, Crowe JE Jr, Jens Meiler J. Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods. Journal of PLoS Computational Biology 2022; 18(12): e1010230. PMC ID 9762601.
Desautels TA, Arrildt KT, Zemla AT, Lau EY, Zhu F, Ricci D, Cronin S, Zost SJ, Binshtein E, Scheaffer SM, Engdahl TB, Chen E, Goforth JW, Vashchenko D, Nguyen S, Weilhammer DR, Lo JK, Rubinfeld B, Saada EA, Weisenberger T, Lee TH, Whitener B, Case JB, Ladd A, Silva MS, Haluska RM, Grzesiak EA, Bates TW, Petersen BK, Thackray LB, Segelke BW, Lillo AM, Sundaram S, Diamond MS, Crowe JE, Carnahan RH, Faissol DM. Computationally restoring the potency of a clinical antibody against SARS-CoV-2 Omicron subvariants.
Preprint: bioRxiv 2022 October 24, 2022. doi: 10.1101/2022.10.21.513237. Preprint. PMC ID 9628197.
Rghei AD, Yates JGE, Lopes JA, Zhan X, Guilleman MM, Pei Y, van Lieshout LP, Santry LA, Bridle BW, Karimi K, Susta L, Crowe JE Jr Wootton SK. Antibody-based protection against respiratory syncytial virus in mice and their offspring through vectored immunoprophylaxis. Gene Therapy. 2023 Feb 2.
doi: 10.1038/s41434-023-00385-2. Online ahead of print. PMID: 36732618. PMC ID in process.
¬Neuzil KM et al., with Influenza A/H5N8 Virus Vaccine Group (includes Crowe JE Jr). Safety and Immunogenicity of influenza A/H5N8 virus vaccine in healthy adults: Durability and cross-reactivity of antibody responses. Clinical Infectious Diseases 2023 Jan 5;ciac982. doi: 10.1093/cid/ciac982. Online ahead of print. PMID: 36610728.
Pilewski KA, Wall S, Richardson SI, Manamela NP, Clark K, Hermanus T, Binshtein E, Venkat R, Sautto GA, Kramer KJ, Shiakolas AR, Setliff I, Salas J, Mapengo RE, Suryadevara N, Brannon JR, Beebout CJ, Parks R, Raju N, Frumento N, Walker LM, Fechter EF, Qin JS, Murji AA, Janowska K, Thakur B, Lindenberger J, May A, Huang X, Sammour S, Acharya P, Carnahan RH, Ross TM, Haynes BF, Hadjifrangiskou M, Crowe JE Jr, Bailey JR, Kalams S, Morris L, Georgiev IS. Functional HIV-1/HCV cross-reactive antibodies isolated from a chronically co-infected donor. In press, Cell Reports 2023.
Williamson LE*, Bandyopadhyay A*, Bailey K, Sirohi D, Klose T, Julander JG, Kuhn RJ#, Crowe JE Jr#. Structural constraints of human anti-Eastern equine encephalitis virus monoclonal antibodies link differences in neutralization potencies. In press, Proceedings of the National Academy of Sciences USA 2023.
*equal contributions; #co-corresponding
Parrington HM, Kose N, Armstrong N, Handal L, Diaz S, Reidy J, Dong J, Stewart-Jones GBE, Shrivastava-Ranjan P, Jain S, Albariño CG, Carnahan RH, Crowe JE Jr. Potently neutralizing human monoclonal antibodies against the zoonotic pararubulavirus Sosuga virus. JCI Insight 2023; 8(8):e166811. doi: 10.1172/jci.insight.166811. PMID: 36853802
Raju S, Adams LJ, Earnest JT, Vang L, Crowe JE Jr, Fremont DH, Diamond MS. A chikungunya virus-like particle vaccine in humans induces protective neutralizing antibodies against arthritogenic alphaviruses. In press, Science Translational Medicine 2023.
Skinner NE, Ogega CO, Frumento N, Clark KE, Yegnasubramanian S, Cox Al, Crowe JE Jr, Ray SC, Bailey JR. Convergent antibody responses associated with broad neutralization of hepatitis C virus and clearance of infection. In press, Frontiers in Immunology 2023; 14: 1135841. PMC ID 10080129.
Stass R, Engdahl TB, Chapman NS, Handal LS, Diaz SM, Crowe JE Jr*, Bowden TA*. Structural basis for potent neutralization of Sin Nombre hantavirus by a human monoclonal antibody. In press, Nature Microbiology.
Rolsma SL, Yoder SM, Nargi RS, Brady E, Jimenez-Truque N, Thomsen I, Kontos M, Carnahan RH, Sutton RE Armstrong E, Dally L, Crowe JE Jr, Edwards KM, Creech CB. Development of a kinetic ELISA and reactive B cell frequency assay to detect respiratory syncytial virus pre-fusion F protein-specific immune responses in infants. Journal of the Pediatric Infectious Diseases Society 2023 Apr 8;piad019. doi: 10.1093/jpids/piad019. Online ahead of print. PMID: 37029694.
Engdahl TB*, Binshtein E*, Brocato RL*, Kuzmina NA, Principe LM, Kwilas SA, Kim RK, Chapman NS, Porter MS, Guardado-Calvo P, Rey FA, Handal LS, Diaz SM, Zagol-Ikapitte IA, Reidy JX, Andrew Trivette A, Bukreyev A, Hooper JW#, Crowe JE Jr#. Antigenic mapping and functional characterization of human New World hantavirus neutralizing antibodies. eLife2023; 12:e81743. PMC ID 10115451.
*equal contributions; #co-corresponding
Preprint: bioRxiv 2022.07.19.500579; doi: https://doi.org/10.1101/2022.07.19.500579